Search results
Showing 101 to 150 of 646 results for diabetes
Diabetes: annual psychological assessment (children) (IND57)
This indicator covers the proportion of children and young people with diabetes who have received a psychological assessment in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG76
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 64 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM96.
This indicator covers the percentage of patients aged between 25 and 84 years, with type 2 diabetes, without moderate or severe frailty, not currently treated with a statin, who have had a consultation for a full formal cardiovascular disease risk assessment in the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM160
This indicator covers admission rates due to lower limb amputations in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG65
This indicator covers the establishing and maintaining of a register of all patients with a diagnosis of non-diabetic hyperglycaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM148
This indicator covers the proportion of young people aged 12 to 18 years with diabetes who have a record of eye screening in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG72
This indicator covers the proportion of eligible people with diabetes who have not attended for diabetic eye screening in the previous 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG87
This indicator covers the proportion of young people with diabetes age 12 to 18 years who have had their smoking status recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG74
This indicator covers the proportion of young people aged 12 to 18 years with diabetes who have had their urinary albumin recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG70
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM97.
This indicator covers the proportion of eligible people with diabetes who are suspended from diabetic eye screening due to previous screening results. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG89
Diabetes: admission rates (renal replacement therapy) (IND45)
This indicator covers admission rates for renal replacement therapy in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG63
This indicator covers the proportion of children and young people with diabetes who receive individual care processes in the past 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG66
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 58 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM141
This indicator covers the proportion of children and young people with diabetes who have a record of a foot examination in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG73
This indicator covers the percentage of patients with diabetes with a record of testing of foot sensation using a 10 g monofilament within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM131
This indicator covers the percentage of patients with diabetes, on the register, who have had influenza immunisation in the preceding 1 August to 31 March. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM139
Diabetes: structured education within 12 months of diagnosis (IND11)
This indicator covers the proportion of adults with diabetes referred to a structured education programme within 12 months of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG14
Diabetes: blood pressure (without moderate or severe frailty) (IND249)
This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233
This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.
This indicator covers the percentage of patients with non-diabetic hyperglycaemia who have had an HbA1c test or FPG test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM150
This indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM13
Diabetes: statins for primary prevention of CVD (40 years and over) (IND183)
This indicator covers the percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a statin (excluding patients with type 2 diabetes and a cardiovascular disease risk score of less than 10% recorded in the preceding 3 years). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM162
This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a statin. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM163
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (IPG257)
Evidence-based recommendations on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. This involves removing cells called islet cells, which are responsible for the production of insulin, from human donors.
View recommendations for IPG257Show all sections
Sections for IPG257
Diabetes: statins for primary prevention of CVD (T2DM and 10% risk) (IND182)
This indicator covers the percentage of patients with a diagnosis of type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more (without moderate or severe frailty), who are currently treated with a statin (unless there is a contraindication or statin therapy is declined). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM161
This guideline covers how to encourage employees to be physically active. The aim is to increase the working population’s physical activity levels.
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
This quality standard covers treating and managing psychosis and schizophrenia in adults (aged 18 and over) in primary, secondary and community care. It also includes support for the families and carers of people with psychosis or schizophrenia. It describes high-quality care in priority areas for improvement.
View quality statements for QS80Show all sections
Sections for QS80
- Quality statements
- Quality statement 1: Referral to early intervention in psychosis services
- Quality statement 2: Cognitive behavioural therapy
- Quality statement 3: Family intervention
- Quality statement 4: Treatment with clozapine
- Quality statement 5: Supported employment programmes
- Quality statement 6: Assessing physical health
- Quality statement 7: Promoting healthy eating, physical activity and smoking cessation
Weight management: lifestyle services for overweight or obese adults (PH53)
This guideline covers multi-component lifestyle weight management services including programmes, courses, clubs or groups provided by the public, private and voluntary sector. The aim is to help people lose weight and become more physically active to reduce the risk of diseases associated with obesity. This includes coronary heart disease, stroke, type 2 diabetes and various cancers.
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
This indicator covers the percentage of patients with hypertension or diabetes and a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months who have been referred to a weight management programme within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM203
Community pharmacies: promoting health and wellbeing (NG102)
This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.
This guideline covers recognising, assessing and treating bipolar disorder (formerly known as manic depression) in children, young people and adults. The recommendations apply to bipolar I, bipolar II, mixed affective and rapid cycling disorders. It aims to improve access to treatment and quality of life in people with bipolar disorder.
Acute kidney injury: prevention, detection and management (NG148)
This guideline covers preventing, detecting and managing acute kidney injury in children, young people and adults. It aims to improve assessment and detection by non-specialists, and specifies when people should be referred to specialist services. This will improve early recognition and treatment, and reduce the risk of complications in people with acute kidney injury.
This quality standard covers recognising, assessing and managing coeliac disease in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS134Show all sections
Sections for QS134
- Quality statements
- Quality statement 1: Serological testing for coeliac disease
- Quality statement 2: Referral to a specialist
- Quality statement 3: Endoscopic intestinal biopsy
- Quality statement 4: Advice about a gluten-free diet
- Quality statement 5: Annual review
- Update information
- About this quality standard
This guideline covers assessing and treating bedwetting in people aged under 19. It aims to reduce bedwetting and the distress this causes by explaining what to ask in an assessment, what advice to provide, and which treatments are effective.
NICE's impact on managing long-term conditions in children in the community
This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.
Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.
This quality standard covers recognising, assessing and managing bipolar disorder in adults (aged 18 and over) in primary and secondary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS95Show all sections
Sections for QS95
- Quality statements
- Quality statement 1: Referral for specialist mental health assessment
- Quality statement 2: Personalised care plan
- Quality statement 3: Involving carers in care planning
- Quality statement 4 (developmental): Psychological interventions
- Quality statement 5: Maintaining plasma lithium levels
- Quality statement 6: Valproate
- Quality statement 7: Assessing physical health
type 1 diabetes and other types of diabetes: What are the best clinical features or combination of features for...
Evidence-based recommendations on using coronary artery stents in adults.
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic kidney disease in adults.
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS76Show all sections
Sections for QS76
- Quality statements
- Quality statement 1: Raising awareness in people at risk
- Quality statement 2: Identifying acute kidney injury in people admitted to hospital
- Quality statement 3: Response to acute kidney injury warning stage 2 test result
- Quality statement 4: Response to acute kidney injury warning stage 3 test result
- Quality statement 5: Referral for renal replacement therapy
- Quality statement 6: Clinical review after hospital discharge
- Update information
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline covers the nutrition of pregnant women, including women who are planning to become pregnant, mothers and other carers of children aged under 5 and their children. In particular, it aims to address disparities in the nutrition of low-income and other disadvantaged groups compared with the general population.